Crohn’s Disease Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Anti-inflammatory, Immune System Suppressors, Antibiotics, Surgical), By Region, And Segment Forecasts, 2018 - 2025

August 2018 | 100 pages | ID: CCCB79CBA1AEN
Grand View Research, Inc.

Abstracts

The global crohn’s disease therapeutics market size is expected to reach USD 4.7 billion by 2025, according to a new report by Grand View Research, Inc., registering a 2.4% CAGR during the forecast period. Increasing awareness of the disease, coupled with rising initiatives by regulatory bodies for development of novel treatment options, is estimated to provide the market with high growth potential.

For instance, the American Gastroenterological Association (AGA), in collaboration with Pfizer, supports research projects related to inflammatory bowel diseases and has offered three grants in their name. The Crohn’s & Colitis Foundation, European Federation of Crohn’s & Ulcerative Colitis Associations, and American Autoimmune Related Diseases Association are some of the organizations providing funds for research.

Furthermore, increase in prevalence of Crohn’s disease has directed many companies to collaborate with various regulatory bodies and research institutes to introduce novel and effective treatment for the condition. In 2016, Pfizer’s Centers for Therapeutic Innovation (CTI) collaborated with Johns Hopkins University to discover new medicines to treat Crohn’s disease and ulcerative colitis.

Further key findings from the report suggest:

• The global Crohn’s disease therapeutics market size was estimated at USD 3.8 billion in 2016 and is expected to register a CAGR of 2.4% from 2017 to 2025
• Anti-inflammatory emerged as the largest therapy type segment in 2016 due to its efficacy, while immune system suppressors emerged as the fastest growing segment owing to reduction in surgeries and hospitalization rates
• North America dominated in terms of revenue in 2016 owing to rise in prevalence of the disease and increase in involvement of regulatory bodies in terms of funding R&D initiatives
• Asia Pacific is anticipated to witness lucrative growth at a CAGR of over 4.0% over the forecast period due to various developments in healthcare infrastructure and rapid economic development across major emerging economies such as India and China
• Some of the key players in the market are Johnson & Johnson Services Inc.; Pfizer Inc.; Allergan; and AbbVie Inc.

Contents

CHAPTER 1 METHODOLOGY & SCOPE

1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources

CHAPTER 2. EXECUTIVE SUMMARY

2.1. Market Snapshot

CHAPTER 3. CROHN’S DISEASE THERAPEUTICS INDUSTRY OUTLOOK

3.1. Market segmentation
3.2. Market size and growth prospects, 2014 - 2025
3.3. Value chain analysis
3.4. Regulatory Framework
3.5. Market dynamics
  3.5.1. Market driver analysis
  3.5.2. Market restraint analysis
3.6. Key opportunities prioritized
3.7. Industry analysis - Porter's
3.8. PESTEL analysis, 2016

CHAPTER 4. CROHN’S DISEASE THERAPEUTICS: THERAPY TYPE OUTLOOK

4.1. Crohn’s disease therapeutics market share by therapy type, 2014 & 2025 (USD Billion)
4.2. Non-Surgical
  4.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
  4.2.2. Market estimates and forecast by region, 2014 - 2025 (USD Billion)
4.3. Surgical
  4.3.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
  4.3.2. Market estimates and forecast by region, 2014 - 2025 (USD Billion)

CHAPTER 5. CROHN’S DISEASE THERAPEUTICS MARKET: REGIONAL OUTLOOK

5.1. Crohn’s disease therapeutics market share by region, 2015 & 2025 (USD Billion)
5.2. North America
  5.2.1. North America Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
  5.2.2. U.S.
    5.2.2.1. U.S. Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
  5.2.3. Canada
    5.2.3.1. Canada Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
5.3. Europe
  5.3.1. Europe Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
  5.3.2. U.K.
    5.3.2.1. U.K. Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
  5.3.3. Germany
    5.3.3.1. Germany Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
5.4. Asia Pacific
  5.4.1. Asia Pacific Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
  5.4.2. China
    5.4.2.1. China Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
  5.4.3. India
    5.4.3.1. India Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
  5.4.4. Japan
    5.4.4.1. Japan Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
5.5. Latin America
  5.5.1. Latin America Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
  5.5.2. Brazil
    5.5.2.1. Brazil Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
  5.5.3. Mexico
    5.5.3.1. Mexico Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
5.6. Middle East & Africa
  5.6.1. MEA Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
  5.6.2. South Africa
    5.6.2.1. South Africa Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)

CHAPTER 6. COMPETITIVE LANDSCAPE

6.1. Strategy Framework
6.2. Market Participation Categorization

CHAPTER 7. COMPANY PROFILES

7.1. Takeda Pharmaceutical Company Limited
  7.1.1. Company Overview
  7.1.2. Financial Performance
  7.1.3. Product Benchmarking
  7.1.4. Strategic Initiatives
7.2. Allergan Inc.
  7.2.1. Company Overview
  7.2.2. Financial Performance
  7.2.3. Product Benchmarking
  7.2.4. Strategic Initiatives
7.3. Perrigo Company PLC
  7.3.1. Company Overview
  7.3.2. Financial Performance
  7.3.3. Product Benchmarking
  7.3.4. Strategic Initiatives
7.4. Pfizer Inc.
  7.4.1. Company Overview
  7.4.2. Financial Performance
  7.4.3. Product Benchmarking
  7.4.4. Strategic Initiatives
7.5. Johnson & Johnson Services Inc.
  7.5.1. Company Overview
  7.5.2. Financial Performance
  7.5.3. Product Benchmarking
  7.5.4. Strategic Initiatives
7.6. Janssen Biotech Inc.
  7.6.1. Company Overview
  7.6.2. Financial Performance
  7.6.3. Product Benchmarking
  7.6.4. Strategic Initiatives
7.7. Ferring B.V.
  7.7.1. Company Overview
  7.7.2. Financial Performance
  7.7.3. Product Benchmarking
  7.7.4. Strategic Initiatives
7.8. Celgene Corporation
  7.8.1. Company Overview
  7.8.2. Financial Performance
  7.8.3. Product Benchmarking
  7.8.4. Strategic Initiatives
7.9. Genentech Inc.
  7.9.1. Company Overview
  7.9.2. Financial Performance
  7.9.3. Product Benchmarking
  7.9.4. Strategic Initiatives
7.10. Salix Pharmaceuticals
  7.10.1. Company Overview
  7.10.2. Financial Performance
  7.10.3. Product Benchmarking
  7.10.4. Strategic Initiatives
7.11. UCB S.A.
  7.11.1. Company Overview
  7.11.2. Financial Performance
  7.11.3. Product Benchmarking
  7.11.4. Strategic Initiatives
7.12. AbbVie Inc.
  7.12.1. Company Overview
  7.12.2. Financial Performance
  7.12.3. Product Benchmarking
  7.12.4. Strategic Initiatives
7.13. Gilead Sciences Inc.
  7.13.1. Company Overview
  7.13.2. Financial Performance
  7.13.3. Product Benchmarking
  7.13.4. Strategic Initiatives

List Of Tables

LIST OF TABLES

Table 1 Country share estimation
Table 2 North America Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2015 - 2025 (USD Billion)
Table 3 U.S. Crohn’s disease therapeutic market estimates and forecasts, therapy type, 2014 - 2025 (USD Billion)
Table 4 Canada Crohn’s disease therapeutic market estimates and forecasts, therapy type, 2014 - 2025 (USD Billion)
Table 5 Europe Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
Table 6 U.K. Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
Table 7 Germany Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
Table 8 Asia Pacific Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
Table 9 Japan Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
Table 10 China Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
Table 11 India Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
Table 12 Latin America Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
Table 13 Brazil Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
Table 14 Mexico Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
Table 15 MEA Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
Table 16 South Africa Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)

List Of Figures

LIST OF FIGURES

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Value chain based sizing & forecasting
Fig. 4 QFD modeling for market share assessment
Fig. 5 Market summary
Fig. 6 Market trends &outlook
Fig. 7 Market segmentation & scope
Fig. 8 Market driver relevance analysis (Current & future impact)
Fig. 9 Crohn’s disease therapeutics pipeline
Fig. 10 Market restraint relevance analysis (Current & future impact)
Fig. 11 Penetration & growth prospect mapping
Fig. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Crohn’s disease therapeutic market Therapy type outlook key takeaways
Fig. 15 Crohn’s disease therapeutic market: Type movement analysis
Fig. 16 Global non-surgical market, 2014 - 2025 (USD Billion)
Fig. 17 Global Anti-inflammatory drugs market, 2014 - 2025 (USD Billion)
Fig. 18 Global Immune system suppressors market, 2014 - 2025 (USD Billion)
Fig. 19 Global Antibiotics market, 2014 - 2025 (USD Billion)
Fig. 20 Global other medications market, 2014 - 2025 (USD Billion)
Fig. 21 Global Surgical market, 2014 - 2025 (USD Billion)
Fig. 22 Regional market place: Key takeaways
Fig. 23 Regional outlook, 2015 & 2024
Fig. 24 North America Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 25 U.S. Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 26 Canada Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 27 Europe Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 28 U.K. Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 29 Germany Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 30 Asia Pacific Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 31 Japan Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 32 China Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 33 India Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 34 Latin America Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 35 Brazil Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 36 Mexico Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 37 MEA Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 38 South Africa Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Fig. 39 Strategy framework
Fig. 40 Participant categorization